X-ZELL part of Galen Growth’s 2020 HealthTech Cohort

X-ZELL part of Galen Growth’s 2020 HealthTech Cohort Singapore, May 2020 – X-ZELL is one of 23 start-ups selected to be part of Galen Growth’s inaugural HealthTech Cohort, an acceleration and networking initiative designed to champion healthcare innovation from across...

Essex Bio-Technology joins X-ZELL Seed+ Investment Round

Essex Bio-Technology Joins X-ZELL Seed+ Investment Round Singapore/Hong Kong, April 2020 – Rare cell detection specialist X-ZELL has entered into an investment agreement with Essex Bio-Investment, a wholly owned subsidiary of Essex Bio-Technology Ltd (“EssexBio”)....

X-ZELL featured in German life science magazine Laborjournal

X-ZELL featured in German life science magazine Laborjournal Freiburg, April 2020 – X-ZELL has been featured in the April edition of Laborjournal, one of Germany’s leading life science publications.    The extensive company profile, penned by science journalist Dr...

Interview: Krebs im Blut

INTERVIEW Krebs im BLUT Due to the overwhelming response to X-ZELL’s recent Live Sessions tour around Germany, we sat down with X-ZELL Founder & CEO, Dr Sebastian Bhakdi, to interview him in his native language.  Singapur, Februar 2020 – Der deutsche Arzt Dr....

X-ZELL Cryoimmunostaining™ technology touring Europe

X-ZELL Cryoimmunostaining™ technology live in Europe Brussels, February 2020 – Following the official European launch of X-ZELL’s Cryoimmunostaining™ Suite in November 2019, the Singapore start-up will be holding a series of Live Sessions in 2020 in order to introduce...

X-ZELL to be featured at Phar-East 2020 in Singapore

X-ZELL cancer detection technology on show at Phar-East 2020 Singapore, February 2020 – X-ZELL has been selected as one of 50 start-ups to be featured at the upcoming Phar-East Summit in Singapore. To be held between 30 June and 1 July at the Resorts World Convention...